2024年3月10日发(作者：萧真)
专利内容由知识产权出版社提供
专利名称：BIOMARKER COMBINATIONS IN EX VIVO
LUNG PERFUSION (EVLP) PERFUSATE
发明人：KESHAVJEE, Shafique,LIU, Mingyao,CYPEL,
Marcelo,SAGE, Andrew
申请号：CA2019/051813
申请日：20191213
公开号：WO2020/118452A1
公开日：20200618
专利附图：
摘要：Methods and kits for screening, diagnosing, detecting or predicting a patient
outcome/risk variable for a lung transplant recipient after transplant or an EVLP outcome
by measuring biomarker levels of at least three biomarkers selected from IL-6, IL-8, IL-10
and IL-1β optionally in combination with one or both of sTNFR1 and sTREM1 in EVLP
perfusate are described. The methods involve for example, i. obtaining one or more test
EVLP perfusate samples of a donor lung; ii. determining in one or more test EVLP
perfusate sample of a donor lung, a polypeptide level of the at least three biomarkers
selected from IL-8, IL-6, IL-10 and IL-1β and optionally one or both of sTNFR1 and
sTREM1 i; and iii. a) comparing the one or more parameter values related to a level of the
at least three biomarkers in the perfusate sample with control EVLP data or a cut-off
level, wherein the differential level is indicative of outcome/risk of after transplant or of
an EVLP outcome; or b) using the one or more parameter values related to a level of the
at least three biomarkers in combination, as part of an algebraic calculation or model of
outcome/risk.
申请人：UNIVERSITY HEALTH NETWORK
地址：190 Elizabeth Street R. Fraser Elliott Building - Room 1S-417 Toronto, Ontario
M5G 2C4 CA
国籍：CA
代理人：BERESKIN & PARR LLP/S.E.N.C.R.L., S.R.L.
更多信息请下载全文后查看
2024年3月10日发(作者：萧真)
专利内容由知识产权出版社提供
专利名称：BIOMARKER COMBINATIONS IN EX VIVO
LUNG PERFUSION (EVLP) PERFUSATE
发明人：KESHAVJEE, Shafique,LIU, Mingyao,CYPEL,
Marcelo,SAGE, Andrew
申请号：CA2019/051813
申请日：20191213
公开号：WO2020/118452A1
公开日：20200618
专利附图：
摘要：Methods and kits for screening, diagnosing, detecting or predicting a patient
outcome/risk variable for a lung transplant recipient after transplant or an EVLP outcome
by measuring biomarker levels of at least three biomarkers selected from IL-6, IL-8, IL-10
and IL-1β optionally in combination with one or both of sTNFR1 and sTREM1 in EVLP
perfusate are described. The methods involve for example, i. obtaining one or more test
EVLP perfusate samples of a donor lung; ii. determining in one or more test EVLP
perfusate sample of a donor lung, a polypeptide level of the at least three biomarkers
selected from IL-8, IL-6, IL-10 and IL-1β and optionally one or both of sTNFR1 and
sTREM1 i; and iii. a) comparing the one or more parameter values related to a level of the
at least three biomarkers in the perfusate sample with control EVLP data or a cut-off
level, wherein the differential level is indicative of outcome/risk of after transplant or of
an EVLP outcome; or b) using the one or more parameter values related to a level of the
at least three biomarkers in combination, as part of an algebraic calculation or model of
outcome/risk.
申请人：UNIVERSITY HEALTH NETWORK
地址：190 Elizabeth Street R. Fraser Elliott Building - Room 1S-417 Toronto, Ontario
M5G 2C4 CA
国籍：CA
代理人：BERESKIN & PARR LLP/S.E.N.C.R.L., S.R.L.
更多信息请下载全文后查看